Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Aug 16.

Published in final edited form as: Vaccine. 2017 Jul 14;35(35 Pt B):4569–4577. doi: 10.1016/j.vaccine.2017.07.016

IgG1 (Panel A) and IgG2a levels (Panel B) are shown in serum from mice on day 21 following i.m. vaccination with an inactivated influenza virus (IIV) vaccine containing CaPNP or Alhydrogel (alum) as adjuvant. Data reported for IgG1 include 10 mice/group, IgG2a includes 5 mice/group. On top of the bars, “*” represent a significant increase (*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001) compared to saline (PSS) and CaPNP only controls (placebos) in 1-way ANOVA/Turkey test. Significant differences (*P<0.05) between groups are linked by brackets.

IgG1 (Panel A) and IgG2a levels (Panel B) are shown in serum from mice on day 21 following i.m. vaccination with an inactivated influenza virus (IIV) vaccine containing CaPNP or Alhydrogel (alum) as adjuvant. Data reported for IgG1 include 10 mice/group, IgG2a includes 5 mice/group. On top of the bars, “*” represent a significant increase (*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001) compared to saline (PSS) and CaPNP only controls (placebos) in 1-way ANOVA/Turkey test. Significant differences (*P<0.05) between groups are linked by brackets.